@article{Deprimo.2006,
  abstract = {578 Background: Sunitinib malate (SU11248) is a multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activity that specifically inhibits VEGFR, PDGFR, KIT, RET and FLT3. In a phase II trial of 64 patients with refractory, metastatic breast cancer, sunitinib treatment resulted in an [~]11% objective response rate (Miller et al, ASCO 2005). To characterize potential biomarkers of biological response to sunitinib, we analyzed plasma levels of a panel of soluble proteins from patients in this trial. Methods: Patients received sunitinib in 6-week cycles comprised of 50 mg/day for 4 weeks followed by 2 weeks off treatment. Pre-dose plasma samples from 62 patients were obtained on days 1, 14, and 28 of the first cycle and days 1 and 28 of subsequent cycles. Plasma levels of VEGF, soluble VEGF receptor 2 (sVEGFR-2), soluble KIT (sKIT), and a novel biomarker, sVEGFR-3, were measured via ELISA analysis. Results: Plasma levels of each protein were modulated in most patients d},
  added-at = {2010-02-05T11:28:39.000+0100},
  author = {Deprimo, S. E. and Friece, C. and Huang, X. and Smeraglia, J. and Sherman, L. and Collier, M. and Baum, C. and Elias, A. D. and Burstein, H. J. and Miller, K. D.},
  biburl = {http://www.bibsonomy.org/bibtex/2c051401322a1f486c5abd101be04bb7c/kanefendt},
  interhash = {78b24b80153edacd7fb67e831ddd9806},
  intrahash = {c051401322a1f486c5abd101be04bb7c},
  journal = {J Clin Oncol (Meeting Abstracts)},
  keywords = {Outcome Proteins Research SU11248 Treatment Tyrosine analysis methods protein response therapy},
  number = {18_suppl},
  pages = 578,
  timestamp = {2010-02-05T11:28:39.000+0100},
  title = {Effect of treatment with sunitinib malate, a multitargeted tyrosine kinase inhibitor, on circulating plasma levels of VEGF, soluble VEGF receptors 2 and 3, and soluble KIT in patients with metastatic breast cancer},
  url = {http://meeting.jco.org/cgi/content/abstract/24/18_suppl/578},
  volume = 24,
  year = 2006
}